45

## Claims

1. Use of a GLP-1 agonist for the manufacture of a medicament for lowering total serum lip-
ids.

5

2. Use of a GLP-1 agonist for the manufacture of a medicament for lowering LDL.

3. Use of a GLP-1 agonist for the manufacture of a medicament for lowering smal, dense
LDL

10

4. Use of a GLP-1 agonist for the manufacture of a medicament for lowering VLDL.

5. Use of a GLP-1 agonist for the manufacture of a medicament for lowering triglycerides.

15   6. Use of a GLP-1 agonist for the manufacture of a medicament for lowering cholesterol.

7.  Use of a GLP-1 agonist for the manufacture of a medicament for increasing HDL.

8. Use of a GLP-1 agonist for the manufacture of a medicament for lowering plasma levels of
20  Lp(a) in a human.

9. Use of a GLP-1 agonist for the manufacture of a medicament for inhibiting generation of
apo(a) in a human.

25   10. Use of a GLP-1 agonist for the manufacture of a medicament for treating dyslipidemia.

11. The use according to any one of claims 1-10 wherein the GLP-1 agonist binds to a GLP-1
receptor with an affinity constant, $K_D$, below 1 $\mu$M.

30   12. The use according to any one of claims 1-11 wherein the GLP-1 agonist is selected from
$Arg^{26}$, $Lys^{34}$(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1(7-37), $Arg^{34}$, $Lys^{26}$(N-ε-(γ-Glu(N-α-
hexadecanoyl)))-GLP-1(7-37), exendin-3, exendin-4, $Val^{8}$-GLP-1(7-37), $Thr^{8}$- GLP-1(7-37),
$Met^{8}$- GLP-1(7-37), $Gly^{8}$-GLP-1(7-37).

13. A method of lowering total serum lipids, which method comprises administering to a subject an effective amount of a GLP-1 agonist.

14. A method of lowering LDL, which method comprises administering to a subject an effective amount of a GLP-1 agonist.

15. A method of lowering small, dense LDL, which method comprises administering to a subject an effective amount of a GLP-1 agonist

16. A method of lowering VLDL, which method comprises administering to a subject an effective amount of a GLP-1 agonist.

17. A method of lowering triglycerides, which method comprises administering to a subject an effective amount of a GLP-1 agonist.

18. A method of lowering cholesterol, which method comprises administering to a subject an effective amount of a GLP-1 agonist.

19. A method of increasing HDL, which method comprises administering to a subject an effective amount of a GLP-1 agonist.

20. A method of inhibiting generation of apo(a) in vitro or in vivo by administering a GLP-1 agonist.

21. A method of lowering plasma levels of Lp(a) in a human, comprising administering to said human an effective amount of a GLP-1 agonist.

22. A method of inhibiting generation of apo(a) in a human, comprising administering to said human an effective amount of a GLP-1 agonist.

23. A method for treating dyslipideamia which method comprises administering to a subject an effective amount of a GLP-1 agonist.

24. The method according to any one of claims 13-23 wherein the GLP-1 agonist binds to a GLP-1 receptor with an affinity constant, $K_D$, below 1 $\mu$M.

25. The method according to any one of claims 13-23 wherein the GLP-1 agonist is selected from Arg$^{26}$, Lys$^{34}$(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1(7-37), Arg$^{34}$, Lys$^{26}$(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1(7-37), exendin-3, exendin-4, Val$^{8}$-GLP-1(7-37), Thr$^{8}$- GLP-1(7-37),

5     Met$^{8}$- GLP-1(7-37), Gly$^{8}$-GLP-1(7-37)..